HCT_116_CombinationTherapy_Pooled_Project__ENU_Mutagenesis-sc-3139
HCT_116_CombinationTherapy_Pooled_Project__ENU_Mutagenesis
KRAS mutant CRC is currently in clinical trial with a combination of a MEK and Akt inhibitor. These patients will likely develop resistance to this combination. We aim to identify the mechanisms of resistance via ENU mutagenesis, with a view to identifying additional therapeutics which have the ability to overcome this resistance.
ENU used to engender resistance to a combination of a MEK inhibitor and an Akt Inhibitor.